Shares of Genfit S.A. (NASDAQ:GNFT - Get Free Report) dropped 2.8% during trading on Monday . The stock traded as low as $3.50 and last traded at $3.53. Approximately 4,533 shares traded hands during mid-day trading, a decline of 66% from the average daily volume of 13,269 shares. The stock had previously closed at $3.63.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a "buy" rating and issued a $13.00 target price on shares of Genfit in a report on Friday, February 7th.
Read Our Latest Analysis on GNFT
Genfit Price Performance
The company has a debt-to-equity ratio of 0.61, a quick ratio of 3.74 and a current ratio of 3.74. The firm has a 50 day moving average price of $3.70 and a two-hundred day moving average price of $4.31.
Hedge Funds Weigh In On Genfit
A hedge fund recently bought a new stake in Genfit stock. Millennium Management LLC purchased a new position in shares of Genfit S.A. (NASDAQ:GNFT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 166,375 shares of the company's stock, valued at approximately $611,000. Millennium Management LLC owned about 0.33% of Genfit as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 2.24% of the company's stock.
About Genfit
(
Get Free Report)
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Featured Articles
Before you consider Genfit, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genfit wasn't on the list.
While Genfit currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
